Grazoprevir - Merck and Co
Alternative Names: MK-5172Latest Information Update: 08 Sep 2021
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antivirals; Carbamates; Carboxylic acids; Cyclopropanes; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Puerto Rico (PO)
- 08 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in France, Germany, Israel, Australia, Canada, Austria, Puerto Rico, United Kingdom, Sweden, Poland, New Zealand, Lithuania (PO)
- 21 Apr 2021 Merck & Co completes a phase II extension trial for Hepatitis C in Germany, Italy, Sweden, Hungary, France, Denmark, Spain, Finland, Estonia, the Netherlands, Lithuania, Czech Republic, Austria, Poland, Greece, and United Kingdom and USA (PO) (NCT01667081) (EudraCT2012-002232-85)